Furthermore, the administration of anti-TNF-α antibody (infliximab) is effective in improving the clinical status of the patients with Crohn’s disease and the injection of anti-IL-6 receptor antibody in mice with colitis resulted in inhibition of IFN-γ, IL1-β mRNA as well as TNF-α secretion [77, 78]. The gene discussed is IL1B; the disease is Crohn disease.